Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer
Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer
复制标题
DOI：
10.1093/annonc/mdq072
复制
发表时间：
2010-10-01
影响因子：
50.5
通讯作者：
Colleoni, M.
中科院分区：
文献类型：
--
作者：
Cancello, G.;Maisonneuve, P.;Colleoni, M.
患者和方法：我们根据四种化学定义的肿瘤亚型，探索了不同年龄的复发模式：管腔A和管腔B（雌激素受体阳性和/或孕酮受体阳性和人表皮生长因子受体2（HER 2）阳性和/或高Ki-67），HER 2阳性（和）内分泌受体缺失和三阴性，在2970例绝经前pT 1 -3患者中，pN 0 -3和M0乳腺癌。患者年龄< 35岁（315，11%）的复发和死亡风险显著增加[风险比（HR）= 1.65，95%置信区间（CI）1.30-2.10和HR = 1.78，95% CI 1.12-2.85，与具有相似疾病特征的老年患者（2655，89%）相比，考虑到管腔型B [无病生存期（DFS）HR = 1.62，95% CI 1.21-2.18，总生存期（OS）HR = 2.09，95% CI 0.96-4.53]和三阴性患者，这一点是正确的（DFS的HR = 2.04，95% CI 1.11-3.72; OS的HR = 2.20，95% CI 1.10-4.41）乳腺癌，观察到年轻HER 2阳性乳腺癌患者的复发风险最高（HR = 2.37，95%CI 1.12-5.02）。结论：与具有相似疾病特征的老年患者相比，非常年轻的三阴性、管腔型B或HER 2阳性乳腺癌患者预后较差。
Patients and methods: We explored patterns of recurrence by age according to four immunohistochemically defined tumor subtypes: Luminal A and Luminal B (estrogen receptor positive and/or progesterone receptor positive and either human epidermal growth factor receptor 2 (HER2) positive and/or high Ki-67), HER2-positive (and) endocrine receptor absent and Triple Negative, in 2970 premenopausal patients with pT1-3, pN0-3 and M0 breast cancer.Results: Patients < 35 years of age (315, 11%) presented a significantly increased risk of recurrence and death [hazards ratio (HR) = 1.65, 95% confidence interval (CI) 1.30-2.10 and HR = 1.78, 95% CI 1.12-2.85, respectively] when compared with older patients (2655, 89%) with similar characteristics of disease. This was true considering patients with Luminal B [HR = 1.62, 95% CI 1.21-2.18 for disease-free survival (DFS) and HR = 2.09, 95% CI 0.96-4.53 for overall survival (OS)] and with Triple Negative (HR = 2.04, 95% CI 1.11-3.72 for DFS and HR = 2.20, 95% CI 1.10-4.41 for OS) breast cancer, observing the highest risk of recurrence in the younger patients with HER2-positive breast cancer (HR = 2.37, 95% CI 1.12-5.02) when compared with older patients.Conclusions: Very young patients with Triple Negative, Luminal B or HER2-positive breast cancer have a worse prognosis when compared with older patients with similar characteristics of disease.